grow. collaborate. innovate. thrive. ©2011 Endo Pharmaceuticals 13 AMS – STRATEGIC RATIONALE Furthers stated strategy to respond to the changing economics that drive the U.S. healthcare environment • Evolving from a product-driven company to a healthcare solutions provider • Healthcare reform puts a premium on providing cost- effective health solutions • Balances Endo’s integrated business model Strengthens Endo’s core urology franchise • AMS gives Endo scale in urology therapeutic space with approximately $1BN in sales • AMS enhances Endo’s ability to offer patients solutions through the entire course of urology treatment options • AMS has solid market share in several niche categories that have grown in the mid-to-high single digit range over the long term Brings scale to devices and services business • Generally shorter, less expensive product development • Favorable pricing and reimbursement flexibility • Higher degree of cash flow sustainability supported by life cycle management through innovation, less product substitution risk and continued volume-driven market growth By acquiring a high-growth asset, will diversify and boost revenue and earnings’ streams • Advances growth on several metrics and is immediately accretive to earnings on a cash basis by $0.60 in 2012. • Further diversifies Endo across Branded Pharmaceuticals, Generic and Devices & Services segments • AMS has a robust product portfolio and a strong product cadence over the next 12 months | 
